Sign In
Buy ABT
$93.24
+2.73 (+3.02%)
At Close: Jun 25, 2026
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
04:09am, Thursday, 04'th Sep 2025
The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching c
Abbott to take $200 million tariff hit: What it means for patients
01:30pm, Wednesday, 03'rd Sep 2025
Abbott's CEO explains what tariffs mean for the company and its patients. Transcript: CAROLINE WOODS: So while you're working on all of that, you're also having to plan for and account for tariffs tha
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
05:32pm, Tuesday, 02'nd Sep 2025
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
10:56am, Monday, 01'st Sep 2025
Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
10:50am, Friday, 29'th Aug 2025
Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, accord
Abbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis
08:00am, Friday, 29'th Aug 2025
Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at lo
Abbott CEO reveals the biggest disruptions in healthcare
02:30pm, Wednesday, 27'th Aug 2025
An inside look into Abbott's momentum across diagnostics and devices, tariff impacts, and how AI will transform healthcare within five years. Transcript: CAROLINE WOODS: Joining me now, Robert Ford, C
Best Dividend Aristocrats For September 2025
02:09pm, Wednesday, 27'th Aug 2025
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
09:41am, Wednesday, 27'th Aug 2025
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
NVST or ABT: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 25'th Aug 2025
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their
Best Dividend Kings: August 2025
10:13pm, Sunday, 24'th Aug 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued
3 Unstoppable Dividend Stocks to Buy Right Now
06:45am, Saturday, 23'rd Aug 2025
How does getting paid to own a stock sound to you? That's exactly what dividends do.
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?
10:31am, Wednesday, 20'th Aug 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 19'th Aug 2025
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott Gains in Nutrition With Adult Segment Leading Growth
09:50am, Monday, 18'th Aug 2025
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
